secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scilex Holding Co (SCLX)
CIK:        0001820190
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001193125-24-046890
Event type: litigation
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scilex Pharma settles Virpax litigation for $3.5M upfront, $2.5M later, plus royalties on three drugs
--------------------------------------------------------------------------------

- Virpax to pay $3.5M by March 1, 2024 and $2.5M by July 1, 2024 to settle the lawsuit.
- Royalties of 6% of annual net sales on Epoladerm, Probudur, and Envelta if ever sold.
- Mutual release with Virpax; litigation against former President Anthony Mack continues.
- Definitive settlement agreement due by March 1, 2024; term sheet binding if not signed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/0001193125-24-046890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1820190/000119312524046890/d795466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-046890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer